Treatment with Inhaled Antibiotics as One of the Measures to Combat Bacterial Resistance (Cystic Fibrosis is Used as an Example)
https://doi.org/10.58838/2075-1230-2024-102-1-82-86
Abstract
This review analyzes 33 publications on the effectiveness of inhaled antibiotics in patients with cystic fibrosis and evaluates their effect on bacterial resistance.
About the Author
A. V. Takhtamysheva
Donetsk Center for Primary Medical Sanitary Care no. 9
DNR
DNR
Anna V. Takhtamysheva, General Practitioner
1 Dikkens St., Donetsk, 283005
References
1. Klinicheskiye rekomendatsii po vedeniyu patsiyentov s kistoznym fibrozom (mukovistsidozom). [Guidelines on management of cystic fibrosis patients]. Moscow, 2021. Available: https://cr.minzdrav.gov.ru/recomend/372_2 Accessed December 10, 2023.
2. Kuzovlev A.N., Moroz V.V., Golubev A.M., Polovnikov S.G. Inhaled antibiotics in the treatment of nosocomial pneumonia. Obschaya Reanimatologiya, 2013, vol. 9, no. 6, pp. 61-70. (In Russ.) https://doi.org/10.15360/1813-9779-2013-6-61
3. Chukina M.A., Lukina M.V., Andruschishina T.B. et al. Inhaled amikacin in patients with nosocomial pneumonia in the intensive care unit. Vestnik Smolenskoy Gosudarstvennoy Meditsinskoy Akademii, 2019, vol. 18, no. 1, pp. 137-144. (In Russ.)
4. Bassetti M., Luyt C.E., Nicolau D.P., Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann. Intensive Care, 2016, vol. 6, no. 1, pp. 35. https://doi.org/10.1186/s13613-016-0140-x PMID: 27090532
5. Choi J., Novak K., Thompson R. Evaluation of inhaled tobramycin in early eradication of Pseudomonas aeruginosa in infants with cystic fibrosis. J. Pediatr. Pharmacol. Ther., 2020, vol. 25, no. 8, pp. 709-716. https://doi.org/10.5863/1551-6776-25.8.709 PMID: 33214782
6. ClinicalTrials.gov: NCT01270347 Trial of aeroquin versus tobramycin inhalation solution (TIS) in cystic fibrosis (CF) patients (TIS). Available: ehttps://ichgcp.net/clinical-trials-registry/NCT01270347 Accessed December 15, 2022
7. Daniels T., Mills N., Whitaker P. Nebuliser systems for drug delivery in cystic fibrosis. Cochrane Database Syst. Rev., 2013, vol. 30, no. 4, pp. CD007639. https://doi.org/10.1002/14651858 PMID:23633344
8. Dasenbrook E.C., Konstan M.W., VanDevanter D.R. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J. Cyst. Fibros., 2015, vol. 14, no. 3, pp. 370-5. https://doi.org/10.1016/j.jcf.2014.11.005 PMID: 25496726
9. Dezube R., Jennings M.T., Rykiel M., Diener-West M., Boyle M.P., Chmiel J.F., Dasenbrook E.C. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J. Cyst. Fibros., 2019, vol. 18, no. 3, pp. 357-363. https://doi.org/10.1016/j.jcf.2018.07.005 PMID: 30131297
10. Ekkelenkamp M.B., Díez-Aguilar M., Tunney M.M., Elborn J.S., Fluit A.C., Cantón R. Establishing antimicrobial susceptibility testing methods and clinical breakpoints for inhaled antibiotic therapy. Open Forum Infect. Dis., 2022, vol. 9, no. 4, pp. ofac082. https://doi.org/10.1093/ofid/ofac082 PMID: 35265731
11. Elborn J.S., Flume P.A., Cohen F., Loutit J., VanDevanter D.R. Safety and efficacy of prolonged levofloxacin inhalation solution (APT-1026) treatment for cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. J. Cyst. Fibros., 2016, vol. 15, no. 5, pp. 634-40. https://doi.org/10.1016/j.jcf.2016.01.005 PMID: 26935334
12. Goetz D., Ren C.L. Review of cystic fibrosis. Pediatr. Ann., 2019, vol. 48, no. 4, pp. e154-e161. https://doi.org/10.3928/19382359-20190327-01 PMID: 30986316
13. Hatziagorou E., Orenti A., Drevinek P., Kashirskaya N., Mei-Zahav M., De Boeck K; ECFSPR. Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry. J. Cyst. Fibros., 2020, vol. 19, no. 3, pp. 376-383. https://doi.org/10.1016/j.jcf.2019.08.006 PMID: 31492646
14. Henriette Zweijpfenning S.M., Chiron R., Essink S., Schildkraut J., Akkerman O.W., Aliberti S., Altenburg J., Arets B., van Braeckel E., Delaere B., Gohy S., Haarman E., Lorent N., McKew G., Morgan L., Wagner D., van Ingen J., Hoefsloot W. Safety and outcomes of amikacin liposome inhalation suspension for Mycobacterium abscessus pulmonary disease: A NTM-NET study. Chest, 2022, vol. 162, no. 1, pp. 76-81. https://doi.org/10.1016/j.chest.2022.01.015 PMID: 35063454
15. Hoo Z.H., Curley R., Campbell M.J., Walters S.J., Hind D., Wildman MJ. Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence". Patient Prefer Adherence, 2016, vol. 23, no. 10, pp. 887-900. https://doi.org/10.2147/PPA.S105530 PMID: 27284242
16. Jennings M.T., Boyle M.P., Weaver D., Callahan K.A., Dasenbrook E.C. Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis – the PMEP trial: study protocol for a randomized controlled trial. Trials, 2014, no. 15, pp. 223. https://doi.org/10.1186/1745-6215-15-223 PMID: 24925006
17. Jones L.A., Doucette L., Dellon E.P., Esther C.R., McKinzie C.J. Use of inhaled imipenem/cilastatin in pediatric patients with cystic fibrosis: A case series. J. Cyst. Fibros., 2019, vol. 18, no. 4, pp. e42-e44. https://doi.org/10.1016/j.jcf.2019.04.017 PMID: 31060800
18. Karampitsakos T., Papaioannou O., Kaponi M., Kozanidou A., Hillas G., Stavropoulou E., Bouros D., Dimakou K. Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis. Pulm. Pharmacol. Ther., 2020, no. 60, pp. 101885. https://doi.org/10.1016/j.pupt.2019.101885 PMID: 31891761
19. Kiefer A., Bogdan C., Melichar V.O. Successful eradication of newly acquired MRSA in six of seven patients with cystic fibrosis applying a short-term local and systemic antibiotic scheme. BMC Pulm. Med., 2018, vol. 18, no. 1, pp. 20. https://doi.org/10.1186/s12890-018-0588-6 PMID: 29370836
20. Kuzovlev A.N. Inhaled Antibiotics in Reanimatology: Problem State and Development Prospects (Review). A.N. Kuzovlev, A.V. Grechko. General Reanimatology, 2017, vol. 13, no. 5, pp. 69-84. https://doi.org/10.15360/1813-9779-2017-5-69-84
21. Langton Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst. Rev., 2017, vol. 4, no. 4, pp. CD004197. https://doi.org/10.1002/14651858.CD004197.pub5 PMID: 28440853
22. Lebeaux D., Chauhan A., Rendueles O., Beloin C. From in vitro to in vivo Models of Bacterial Biofilm-Related Infections. Pathogens, 2013, vol. 2, no. 2, pp. 288-356. https://doi.org/10.3390/pathogens2020288 PMID: 25437038
23. Lebeaux D., Ghigo J.M., Beloin C. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol. Mol. Biol. Rev., 2014, vol. 78, 3. pp. 510-43. https://doi.org/10.1128/MMBR.00013-14 PMID: 25184564
24. Møller R., Nielsen B.U., Faurholt-Jepsen D., Katzenstein T.L., Skov M., Philipsen L.KD, Pressler T., Johansen H.K, Qvist T. Use of inhaled antibiotics among Danish patients with cystic fibrosis. Pediatr. Pulmonol., 2022, vol. 57, no. 7, pp. 1726-1734. https://doi.org/10.1002/ppul.25942 PMID: 35478387
25. Quon B.S., Goss C.H., Ramsey B.W. Inhaled antibiotics for lower airway infections. Ann. Am. Thorac. Soc., 2014, vol. 11, no. 3, pp. 425-34. https://doi.org/10.1513/AnnalsATS.201311-395FR PMID: 24673698
26. Riveiro V., Casal A., Álvarez-Dobaño J.M., Lourido T., Suárez-Artime P., Rodríguez-García C., Ferreiro L., Toubes M.E., Valdés L. Response to inhaled ceftazidime in patients with non-cystic fibrosis bronchiectasis and chronic bronchial infection unrelated to Pseudomonas aeruginosa. Clin. Respir. J., 2022, vol. 16, no. 11, pp. 768-773. https://doi.org/10.1111/crj.13534 PMID: 36017771
27. Stockmann C., Sherwin C.M., Ampofo K., Spigarelli M.G. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther. Adv. Respir. Dis., 2014, vol. 8, no. 1, pp. 13-21. https://doi.org/10.1177/1753465813508445 PMID: 24334337
28. Tiddens H.A., Bos A.C., Mouton J.W., Devadason S., Janssens H.M. Inhaled antibiotics: dry or wet? Eur. Respir. J., 2014, vol. 44, no. 5, pp. 1308-18. https://doi.org/10.1183/09031936.00090314 PMID: 25323242
29. Vázquez-Espinosa E., Girón R.M., Gómez-Punter R.M., García-Castillo E., Valenzuela C., Cisneros C., Zamora E., García-Pérez F.J., Ancochea J. Long-term safety and efficacy of tobramycin in the management of cystic fibrosis. Ther. Clin. Risk Manag., 2015, no. 11, pp. 407-15. https://doi.org/10.2147/TCRM.S75208 PMID: 25792839
30. Wang M., Ridderberg W., Hansen C.R., Høiby N., Jensen-Fangel S., Olesen H.V., Skov M., Lemming L.E., Pressler T., Johansen H.K., Nørskov-Lauritsen N. Early treatment with inhaled antibiotics postpones next occurrence of Achromobacter in cystic fibrosis. J. Cyst. Fibros., 2013, vol. 12, no. 6, pp. 638-43. https://doi.org/10.1016/j.jcf.2013.04.013 PMID: 23727271
31. Weldrick P.J., Hardman M.J., Paunov V.N. Enhanced Clearing of Wound-Related Pathogenic Bacterial Biofilms Using Protease-Functionalized Antibiotic Nanocarriers. ACS Appl. Mater. Interfaces, 2019, vol. 11, 47. pp. 43902-43919. https://doi.org/10.1021/acsami.9b16119 PMID: 31718141
32. White L., Mirrani G., Grover M., Rollason J., Malin A., Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir. Med., 2012, vol. 106, no. 3, pp. 356-60. https://doi.org/10.1016/j.rmed.2011.11.018 PMID: 22204744
33. Zobell J.T., Epps K.L., Young D.C., Montague M., Olson J., Ampofo K., Chin M.J., Marshall B.C., Dasenbrook E. Utilization of antibiotics for methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. Pediatr. Pulmonol., 2015, vol. 50, vol. 6, pp. 552-9. https://doi.org/10.1002/ppul.23132 PMID: 25559432
Review
For citations:
Takhtamysheva A.V. Treatment with Inhaled Antibiotics as One of the Measures to Combat Bacterial Resistance (Cystic Fibrosis is Used as an Example). Tuberculosis and Lung Diseases. 2024;102(1):82-86. (In Russ.) https://doi.org/10.58838/2075-1230-2024-102-1-82-86
Views:
387
Email this article 